中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2010年
21期
2913-2914
,共2页
卵巢肿瘤%奈达铂%表柔比星%异环磷酰胺
卵巢腫瘤%奈達鉑%錶柔比星%異環燐酰胺
란소종류%내체박%표유비성%이배린선알
Ovarian neoplasm%Ifosfamide%Nedaplatin%Pharmorubicin
目的 探讨奈达铂、表柔比星及异环磷酰胺联合治疗复发性卵巢癌的疗效和安全性.方法 16例复发性卵巢癌患者采用奈达铂150 mg+0.9%氯化钠注射液500 ml静脉滴注,第1天;表柔比星40 mg+5%葡萄糖注射液50 ml,静脉滴注,第1~2天;异环磷酰胺2.0 g+0.9%氯化钠注射液500 ml,静脉滴注,第1~5天.观察临床治疗效果及不良反应发生情况.结果 16例复发性卵巢癌患者经治疗后,完全缓解1例,部分缓解6例,稳定7例,进展2例,总有效率43.75%(7/16).主要不良反应为骨髓抑制及胃肠道反应.结论 奈达铂、表柔比星及异环磷酰胺联合治疗复发性卵巢癌疗效肯定,不良反应可耐受,值得临床推广.
目的 探討奈達鉑、錶柔比星及異環燐酰胺聯閤治療複髮性卵巢癌的療效和安全性.方法 16例複髮性卵巢癌患者採用奈達鉑150 mg+0.9%氯化鈉註射液500 ml靜脈滴註,第1天;錶柔比星40 mg+5%葡萄糖註射液50 ml,靜脈滴註,第1~2天;異環燐酰胺2.0 g+0.9%氯化鈉註射液500 ml,靜脈滴註,第1~5天.觀察臨床治療效果及不良反應髮生情況.結果 16例複髮性卵巢癌患者經治療後,完全緩解1例,部分緩解6例,穩定7例,進展2例,總有效率43.75%(7/16).主要不良反應為骨髓抑製及胃腸道反應.結論 奈達鉑、錶柔比星及異環燐酰胺聯閤治療複髮性卵巢癌療效肯定,不良反應可耐受,值得臨床推廣.
목적 탐토내체박、표유비성급이배린선알연합치료복발성란소암적료효화안전성.방법 16례복발성란소암환자채용내체박150 mg+0.9%록화납주사액500 ml정맥적주,제1천;표유비성40 mg+5%포도당주사액50 ml,정맥적주,제1~2천;이배린선알2.0 g+0.9%록화납주사액500 ml,정맥적주,제1~5천.관찰림상치료효과급불량반응발생정황.결과 16례복발성란소암환자경치료후,완전완해1례,부분완해6례,은정7례,진전2례,총유효솔43.75%(7/16).주요불량반응위골수억제급위장도반응.결론 내체박、표유비성급이배린선알연합치료복발성란소암료효긍정,불량반응가내수,치득림상추엄.
Objective To investigate the treatment effectsand safety of ifosfamide,nedaplatin with pharmorubicin in relapsed ovarian carcinoma.Methods Sixteen relapsed ovarian carcinoma patients received nedaplatin 150mg in 0.9% sodium chloride 500ml dl,intravenously;pharmorubicin 40mg in 5% glucose 50 ml d1-2,intravenously;and ffosfamide 2.0g in 0.9% sodium chloride 500ml d1-5,intravenously.And the treatment effects and side effects were investigated.Results Of the sixteen patients,one had a complete response,six had a partial response,seven had stable disease,and two had progressive disease.The overall response rate was 43.75%(7/16).The major side effects were bone marrow suppression and gastrointestinal reaction.Conclusion Combination of ffosfamide,nedaplatin and pharmorubicin were very effective in relapsed ovarian carcinoma and the side effects were tolerable.Therefore the regimen is worth promoting in the clinical application.